Earnings call transcript: QuidelOrtho Q3 2026 profit beat overshadowed by revenue miss

QuidelOrtho beat Q3 adjusted EPS estimates at $0.31 versus $0.20, but revenue of $618.9 million missed forecasts by $9.18 million and fell 12% year over year on a constant-currency basis. China revenue declined 45% and point-of-care revenue fell 27%; the company narrowed 2026 revenue guidance to $2.52 billion–$2.54 billion and expects more than $80 million in annual restructuring savings in 2027, alongside $30 million–$35 million in Q4 charges. Shares fell 6.62% after hours to $13.16 as investors appeared more focused on sales pressure and cautious guidance than the earnings beat.

Analysis

The key issue is earnings quality, not the beat: reported profitability benefited from roughly 300bp of non-repeatable gross-margin items, while weaker sales increased opex as a share of revenue. That makes the near-term cash-flow improvement less persuasive until it persists without lower capex or working-capital release. For an equity backed by substantial debt, EBITDA slippage can disproportionately pressure equity value; the covenant amendment buys execution time, but is not evidence that deleveraging is solved.

Management’s claimed $80m-plus of incremental 2027 savings could offset the China shock, but the bridge is unproven: savings ramp later, restructuring consumes cash first, and China faces simultaneous destocking, reimbursement pressure and competition. Respiratory seasonality is a potential upside catalyst, but an early start alone does not establish higher test volumes. Core Labs and immunohematology growth offers a floor, not yet proof it can offset declining point-of-care demand.

Days: the post-earnings gap reflects a reset in confidence; chasing a short after the drop risks a sharp rebound. Over 1–3 months, watch Q4 respiratory utilization, China orders, and operating cash flow. Over 6–18 months, the thesis turns on realized savings, stable core growth and net leverage. The bearish view is falsified by sustained positive free cash flow after restructuring cash costs, savings tracking to plan, and China stabilizing without further guidance cuts. A divestiture could accelerate debt reduction, but remains optionality, not a base case.

Key Decisions for Investors

• Avoid adding to an outright short into the after-hours gap. For bearish exposure, consider a defined-risk QDEL put spread only after checking implied volatility and liquidity; the debt/equity asymmetry is attractive, but a relief rally or asset-sale speculation can be violent.
• For existing longs, reduce exposure on rebounds until QDEL demonstrates recurring free cash flow that excludes restructuring outflows and temporary working-capital/capex benefits. Reassess after the next report rather than treating the adjusted-EPS beat as a turn.
• Set a 1–3 month watch alert for China order trends and respiratory test utilization. A further revenue-guidance reduction, missed savings milestones, or continued leverage deterioration strengthens the downside case; stable China demand and improving cash conversion weaken it.
• Do not underwrite the announced savings as fully bankable yet: verify realized run-rate savings against restructuring cash charges and any customer or commercial disruption. The stated target is company guidance, not independently demonstrated earnings.